Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adverum Biotechnologies Inc (NQ: ADVM )

9.560 +0.170 (+1.81%)
Streaming Delayed Price Updated: 9:31 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adverum Biotechnologies Inc

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and... 
Via Benzinga
ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023
ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Adverum Posts New Data From Wet AMD Gene Therapy Trial
Via Benzinga
Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022
Via Benzinga
Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop
There are plenty of penny stocks ready to pop but we have to remember that penny stocks are extremely risky, too. 
Via InvestorPlace
Stocks on the Launchpad: The Next 3 Market Sensations
Navigate the bullish trend in the market by wagering on these three enticing market sensations likely to become multi-bagger investments 
Via InvestorPlace
Unleash Massive Returns With These 3 Top Penny Stocks
Our economy is doing well, and these top penny stocks are in position to benefit from this. Invest now and see strong returns. 
Via InvestorPlace
Topics Economy
Exposures Economy
Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS... 
Via Benzinga
Why Adverum Biotechnologies Stock Is Trading Higher
Adverum will sell the shares at a price per share of $1.20, representing a premium of approximately 20% to its stock's 30-day volume-weighted average price, and the financing is expected to close on... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during... 
Via Benzinga
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Over $14M Bet On Diversified Healthcare Trust? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by over 40 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 47.9% to $0.31 during Wednesday's pre-market session. The company's market cap stands at $11.8 million. 
Via Benzinga
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
Via Benzinga
Adverum Commences Mid-Stage Chronic Eye Disorder Candidate Study
Adverum Biotechnologies (NASDAQ: ADVM) dosed first subject in the LUNA Phase 2 trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
The Daily Biotech Pulse: FDA Signs Off Cancer Therapy Trials For NexImmune, Omega Therapeutics, Endo To Develop Rare Hereditary Skin Disease Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! We're taking a look at the biggest pre-market stock movers for Thursday that investors need to know about! 
Via InvestorPlace
Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
Gainers United Maritime Corporation (NASDAQ: USEA) shares jumped 180.9% to $6.19. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on Wednesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.